Cyclophosphamide and/or Mycophenolate Mofetil With or Without Tacrolimus in Treating Patients Who Are Undergoing a Donor Bone Marrow or Peripheral Stem Cell Transplant for Hematologic Cancer

DISEASE CHARACTERISTICS:

* Diagnosis of 1 of the following hematologic malignancies:

  * Stage II or III multiple myeloma
  * Amyloidosis
  * Myelofibrosis with ≥ 2 of the following high-risk features:

    * Over 55 years of age
    * Hemoglobin \< 10 g/dL
    * WBC \< 3,000/mm\^3 OR \> 10,000/mm\^3
    * Platelet count \< 100,000/mm\^3
    * Cytogenetic abnormalities
  * Mycosis fungoides, meeting 1 of the following criteria:

    * Stage IIB or III disease with evidence of histologic conversion to an aggressive lymphoma

      * Must demonstrate chemosensitivity
    * Stage IV disease
  * Paroxysmal nocturnal hemoglobinuria

    * Not meeting criteria for other bone marrow transplantation (BMT) or treatment studies
  * Diagnosis of 1 of the following hematologic malignancies, for which patient is not eligible for potentially curative allogeneic BMT due to end-organ dysfunction, age 65 to 75, or the amount of prior chemotherapy:

    * Acute myeloid or acute lymphoblastic leukemia

      * High-risk disease in first or second (or further) complete remission
    * Relapsed aggressive non-Hodgkin's lymphoma

      * Not eligible for autologous or standard allogeneic BMT
    * Hodgkin's lymphoma in second or further complete or partial remission

      * Not eligible for autologous or standard allogeneic BMT
    * Myelodysplastic syndromes or myelodysplastic/myeloproliferative diseases

      * Any of the following subtypes:

        * Refractory anemia with excess blasts (RAEB)
        * RAEB in transformation
        * Chronic myelomonocytic leukemia
        * Any morphologic subtype with multiple chromosomal abnormalities
        * Any subset with life-threatening cytopenias in all 3 cell lines, defined as platelet count ≤ 20,000/mm\^3, absolute neutrophil count ≤ 500/mm\^3, and reticulocyte count ≤ 50,000/mm\^3
      * Meets both of the following criteria:

        * Less than 20% blasts by bone marrow biopsy
        * Not eligible for standard allogeneic BMT
      * No refractory anemia with ringed sideroblasts
      * No 5q syndrome
    * Stage III or IV chronic lymphocytic leukemia

      * Not meeting criteria for other BMT studies
    * Chronic myelogenous leukemia in first or second chronic phase

      * Not meeting criteria for other BMT studies or treatment
    * Stage III or IV indolent small lymphocytic or follicular lymphoma

      * Not eligible for autologous or standard allogeneic BMT or other active protocols at Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
* Must have an HLA-identical related donor available

PATIENT CHARACTERISTICS:

Performance status

* ECOG 0-2

Life expectancy

* Not specified

Hematopoietic

* See Disease Characteristics

Hepatic

* Bilirubin ≤ 3.0 mg/dL
* AST ≤ 175 U/L
* ALT ≤ 200 U/L

Renal

* Creatinine ≤ 3.0 mg/dL

Cardiovascular

* LVEF ≥ 30%

Pulmonary

* FEV\_1 ≥ 40% predicted
* Forced vital capacity ≥ 40% predicted

Other

* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
* HIV negative

PRIOR CONCURRENT THERAPY:

Chemotherapy

* See Disease Characteristics